Skip to main content

Table 5 Univariate and multivariate analysis with respect to disease-free survival and overall survival

From: Clinical verification of the relationship between smoking and the immune microenvironment of breast cancer

Parameters

Univariate analysis

Multivariate analysis

Hazard ratio

95% CI

p value

Hazard ratio

95% CI

p value

Disease-free survival

 Age at operation (year)

  ≤ 56

0.614

0.269–1.335

0.220

   

  > 56

 Tumour size (mm)

  ≤ 27.6

1.137

0.525–2.503

0.744

   

  > 27.6

 Skin infiltration

  Negative

1.556

0.455–4.067

0.440

   

  Positive

 Lymph node status

  Negative

2.440

0.933–8.343

0.071

1.677

0.617–5.859

0.331

  Positive

 Ki67

  Negative

0.394

0.180–0.926

0.034

0.770

0.321–1.942

0.568

  Positive

 Intrinsic subtype

  HER2-enriched

1.884

0.828–4.823

0.135

   

  Triple-negative

 ORR

  Non-responders

0.083

0.035–0.210

< 0.001

0.154

0.059–0.426

0.001

  Responders

 Pathological response

  Non-pCR

0.203

0.068–0.499

< 0.001

0.381

0.118–1.059

0.065

  pCR

 TILs

  Low

0.252

0.107–0.553

0.001

0.424

0.167–1.032

0.059

  High

 Pack-years

  Low

0.434

0.127–1.134

0.092

0.567

0.160–1.555

0.289

  High

Overall survival

 Age at operation (year)

  ≤ 56

0.508

0.175–1.338

0.172

   

  > 56

 Tumour size (mm)

  ≤ 27.6

1.123

0.429–2.993

0.811

   

  > 27.6

 Skin infiltration

  Negative

1.939

0.446–5.977

0.335

   

  Positive

 Lymph node status

  Negative

2.778

0.781–17.657

0.125

   

  Positive

      

 Ki67

  Negative

0.638

0.234–2.023

0.419

   

  Positive

 Intrinsic subtype

  HER2-enriched

1.610

0.597–5.060

0.357

   

  Triple-negative

 ORR

  Non-responders

0.077

0.026–0.238

< 0.001

0.451

0.044–0.520

0.004

  Responders

 Pathological response

  Non-pCR

0.183

0.042–0.561

0.002

0.282

0.062–0.953

0.041

  pCR

 TILs

  Low

0.357

0.129–0.929

0.035

0.634

0.212–1.861

0.403

  High

 Pack-years

  Low

0.554

0.128–1.700

0.325

   

  High

  1. OS overall survival, CI confidence intervals, HER human epidermal growth factor receptor, ORR objective response rate, pCR pathological complete response, TILs tumour-infiltrating lymphocytes